news
Remetinostat shows promise as a BCC treatment in Phase II study
Remetinostat, a first-in-class histone deacetylase inhibitor gel, displayed signs of clinical efficacy in patients with basal cell carcinoma.
List view / Grid view
Basal cell carcinoma (BCC)
news
First immunotherapy for advanced basal cell carcinoma approved in US
In trials Libtayo® caused clinically meaningful and durable responses, resulting in the drug being fully approved for advanced basal cell carcinoma resistant to other treatments.
news
Zoledronic acid could be used to treat basal-like breast cancer
Researchers have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer...
news
Roche’s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
15 July 2013 | By Roche
The European Commission has granted conditional approval to Erivedge...
